Frequent coffee, chocolate consumption reduced liver enzymes in HIV/HCV coinfected patients
Carrieri MP. J Hepatol. 2013;doi:10.1016/j.jhep.2013.08.014.
August 29, 2013
Patients coinfected with HIV and HCV who reported eating chocolate daily and drinking three or more cups of coffee a day had lower levels of ALT and AST than those who consumed fewer polyphenol-rich foods in a recent study.
Researchers evaluated data collected from 990 adult patients coinfected with HCV and HIV enrolled in the ANRS CO13 HEPAVIH prospective cohort study. Patients with cirrhosis had follow-up visits every 6 months, while noncirrhotic participants had annual visits, with liver biochemistry assessed at each visit. Participants also responded to annual self-administered questionnaires regarding sociodemographic status and dietary and drug habits.
Continue reading...
Interferon-free regimen shows promise for patients with chronic HCV
August 29, 2013
A 24-week interferon-free regimen of sofosbuvir and ribavirin resulted in a high sustained virologic response rate among hepatitis C virus patients with unfavorable treatment characteristics, according to study results published in JAMA.
"This is another important step toward the realization that direct-acting agents in an interferon-free regimen will transform the field of the treatment of chronic hepatitis C virus," study researcher Anthony S. Fauci, MD, director of the National Institute of Allergy and Infectious Diseases, told Infectious Disease News.
Continue reading..
Besifovir noninferior to entecavir for chronic HBV in phase 2b trial
Lai CL. Gut. 2013;doi:10.1136/gutjnl-2013-305138.
August 28, 2013
Patients with chronic hepatitis B treated with besifovir experienced similar outcomes to entecavir recipients, but often required carnitine supplementation, in a recent study.
Continue reading...
New protease inhibitors showing promise for HIV/HCV coinfection
August 28, 2013
This is an exciting time in the treatment of chronic hepatitis C virus infections. As opposed to the antibiotic pipeline, there are a number of new antiviral agents for treatment of hepatitis C in development that may transform the way these patients are treated.
Continue reading...
Researchers evaluated data collected from 990 adult patients coinfected with HCV and HIV enrolled in the ANRS CO13 HEPAVIH prospective cohort study. Patients with cirrhosis had follow-up visits every 6 months, while noncirrhotic participants had annual visits, with liver biochemistry assessed at each visit. Participants also responded to annual self-administered questionnaires regarding sociodemographic status and dietary and drug habits.
Continue reading...
Interferon-free regimen shows promise for patients with chronic HCV
August 29, 2013
A 24-week interferon-free regimen of sofosbuvir and ribavirin resulted in a high sustained virologic response rate among hepatitis C virus patients with unfavorable treatment characteristics, according to study results published in JAMA.
"This is another important step toward the realization that direct-acting agents in an interferon-free regimen will transform the field of the treatment of chronic hepatitis C virus," study researcher Anthony S. Fauci, MD, director of the National Institute of Allergy and Infectious Diseases, told Infectious Disease News.
Continue reading..
Besifovir noninferior to entecavir for chronic HBV in phase 2b trial
Lai CL. Gut. 2013;doi:10.1136/gutjnl-2013-305138.
August 28, 2013
Patients with chronic hepatitis B treated with besifovir experienced similar outcomes to entecavir recipients, but often required carnitine supplementation, in a recent study.
Continue reading...
New protease inhibitors showing promise for HIV/HCV coinfection
August 28, 2013
This is an exciting time in the treatment of chronic hepatitis C virus infections. As opposed to the antibiotic pipeline, there are a number of new antiviral agents for treatment of hepatitis C in development that may transform the way these patients are treated.
Continue reading...
No comments:
Post a Comment